The wealth gap is a health gap. The advertisement from telehealth giant Hims & Hers became the most prominent example of a new rallying cry in healthcare
The only real guidance we have is from the pivotal Cell paper published in 2017 where FOXO4-DRI was introduced to the world, in which the peptide was well-tolerated without any side effects
Brinker's counter-move with Maggiano's is worth noting because it illustrates that GLP-1 adaptation isn't monolithic
it is about having more energy, better mobility, fewer chronic illnesses, and a life that feels fuller and more active
Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid
Microdosing GLP-1s for cosmetic weight loss: Patients are asking me about it, TV and online ads are promoting it, friends are speculating about whos doing it